Abstract
Prognosis of patients with metastatic soft tissue sarcoma remains poor. Whether high-dose chemotherapy with stem cell support improves the long-term outcome for these patients is debatable. We present a prospective, single-institutional phase II study that enrolled 34 soft tissue sarcoma patients with advanced and/or metastatic disease. After four courses of chemotherapy consisting of doxorubicin and ifosfamide, responding patients in at least partial response (PR) were treated with high-dose chemotherapy (n=9); all other patients continued chemotherapy for two more cycles. After standard chemotherapy, PR (n=10), stable disease (SD, n=6) and progressive disease (PD, n=14) were attained for the evaluable patients. Twenty-nine patients died and five are alive with the disease. Median PFS was 11.6 months (range 8-15) for patients treated with high-dose chemotherapy (n=9) vs 5.6 months (range 0-19) for patients treated with standard chemotherapy. Median OS was 23.7 months (range 12-34) vs 10.8 months (range 0-39), respectively. The subgroup of patients treated with high-dose chemotherapy gained significant survival benefit. Nevertheless, high-dose chemotherapy as a possible consolidation strategy remains highly investigational.
References
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SantoroE Rankin
Oct 1, 1995·Critical Reviews in Oncology/hematology·J VerweijT Tursz
Feb 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S JelićI Filipović-Ljesković
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S R PatelR S Benjamin
Aug 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P ReichardtD Crowther
Dec 9, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G SaeterE Hannisdal
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P ReichardtB Dörken
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Van GlabbekeT Tursz
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Y BlayP Biron
Feb 22, 2002·Critical Reviews in Oncology/hematology·Giovanni RostiMaurizio Marangolo
Feb 22, 2002·Critical Reviews in Oncology/hematology·Peter Reichardt
Jun 1, 2004·Bone Marrow Transplantation·B KasperG Egerer
May 12, 2005·Oncology·Bernd KasperGerlinde Egerer
Mar 9, 2007·Oncology·Marcus SchlemmerRolf-Dieter Issels
Mar 4, 2008·Cancer Treatment Reviews·Shailendra VermaUNKNOWN Members of the Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care
Jun 4, 2008·Sarcoma·V H BramwellM L Charette
Jun 4, 2008·Cancer·Nabeel PervaizMichelle Ghert
May 13, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carolyn D SeibBrent T Shoji
Citations
Dec 14, 2011·BMC Cancer·Thomas SchmittGerlinde Egerer
Mar 5, 2011·PloS One·Frank PeinemannMichael Kulig
May 30, 2017·Clinical Oncology : a Journal of the Royal College of Radiologists·H HatcherT Ajithkumar
Nov 5, 2011·Head & Neck·Dong M Shin, Fadlo R Khuri
Oct 25, 2020·ESMO Open·Christoph E HeiligPaolo Pedrazzoli